Abstract
Immunotherapy has revolutionized cancer treatment, yet its efficacy is often limited by cancer cell immune evasion and a dysfunctional tumor microenvironment (TME). Radiotherapy can enhance tumor immunogenicity, but its effects are typically localized. Here, we present biofunctionalized liposome-like nanovesicles (BLNs) derived from irradiated cancer cells using an ethanol-induced shedding process. These BLNs up-regulate calreticulin (CRT) to promote macrophage phagocytosis and reprogram immunosuppressive M2-like macrophages into an anti-tumor M1-like phenotype. In a mouse model of resistant malignant pleural effusion (MPE), intrapleural administration of BLNs combined with a PD-1 inhibitor achieved a 63.6% cure rate and established long-term immunological memory. This strategy offers a potent approach to overcoming immunotherapy resistance.
Introduction
While immune checkpoint inhibitors (ICIs) have transformed oncology, they remain effective for only a minority of patients. Two primary barriers prevent successful eradication: the down-regulation of immune sensors on cancer cell surfaces and the prevalence of an immunosuppressive "cold" tumor microenvironment. Radiotherapy (RT) is known to induce immunogenic cell death, potentially turning "cold" tumors "hot." However, capturing this systemic potential in a deliverable format remains a challenge. This study introduces BLNs as a novel platform to harness the immunogenic properties of irradiated cells for systemic or localized therapy.
Fabrication and Characterization of BLNs
The researchers developed a "top-down" fabrication method that avoids the harsh conditions of traditional nanoparticle synthesis. Cancer cells (LLC or B16-F10) are treated with 20 Gy of radiation and, after 72 hours, exposed to 30% ethanol. The ethanol acts as a surfactant, inducing a pyroptosis-like state where the cell membrane sheds vesicles.
As shown in the figure above, the resulting BLNs typically range from 500 to 700 nm in size. Characterization via proteomics and Western blotting confirmed that BLNs retain critical bioactive proteins and double-stranded DNA (dsDNA) from the parent irradiated cells. Notably, the ethanol stimulation preserves the functionality of membrane proteins like Calreticulin (CRT), a vital "eat me" signal for immune recognition.
Therapeutic Mechanism: Reprogramming the Microenvironment
The efficacy of BLNs stems from two primary mechanisms:
- Enhanced Phagocytosis: By presenting high levels of CRT, BLNs significantly increase the ability of macrophages to engulf cancer cells. Experimental data showed a 1.2-fold increase in phagocytosis compared to standard irradiated microparticles.
- Macrophage Polarization: BLNs act on Tumor-Associated Macrophages (TAMs), flipping them from a pro-tumor M2-like phenotype to an anti-tumor M1-like phenotype. This reprogramming is driven by the dsDNA cargo within the BLNs, which activates the MAPK signaling pathway.
Results in Malignant Pleural Effusion (MPE)
The therapeutic potential was tested in a mouse model of MPE, an advanced-stage cancer often resistant to standard immunotherapy. Intrapleural administration of BLNs increased T cell infiltration and reduced the ratio of regulatory T cells (Tregs) to Th1 cells.
When combined with a PD-1 inhibitor (alpha-PD-1), the treatment achieved a 63.6% cure rate (7 out of 11 mice). Furthermore, cured mice demonstrated resistance to tumor re-challenge, indicating the formation of robust immunological memory, characterized by increased central and effector memory T cells. Safety profiles, including hemanalysis and histopathology of major organs, indicated high biocompatibility and no significant toxicity.
Conclusion and Future Directions
BLNs represent a unique strategy for overcoming immunotherapy resistance by combining the immunogenic benefits of radiotherapy with a deliverable nanovesicle format. While the results in mouse models are promising, clinical translation will require addressing the logistics of producing autologous (patient-derived) BLNs and navigating human tumor heterogeneity. This platform holds potential as a personalized cancer vaccine strategy applicable to various solid tumors.
Summary updated